GLIS3 and breast cancer: This is the first study to show aberrant expression of MEG8, NAV2-AS2, STEAP3-AS1, GLIS3-AS1, LINC00158, AC012640.1 in BC and indicates the potential for prediction of tumour recurrence and assessment of recurrence prognosis in BC patients.